Just as
Mesothelioma attorneys have specific experience and training, patients seek medical experts who have education and experience focused on this type of cancer.
Ohio Mesothelioma attorneys review a patient's records and build a legal case based on the careful and thorough documentation of medical professionals. Although these physicians are not endorsed by this Web site, they do specialize in Mesothelioma treatment and care, evidence that this rare form of cancer requires expert management from medical professionals.
LawInfo Lead Counsel Qualified Mesothelioma Attorneys
W. Roy Smythe, MD
Professor and Chairman/Department of Surgery, Texas A&M University System Health Sciences Center, Scott & White Hospital, Temple, TXPhone: 254-724-2595 Dr. Smythe is currently accruing patients for a protocol involving extrapleural pneumonectomy and Intensity Modulated Radiation Therapy (IMRT).
David C. Rice, MD
Assistant Surgeon and Assistant Professor of Surgery; Director, Mesothelioma Program; Director, Minimally Invasive Surgery Program, Thoracic Surgery/The University of Texas M. D. Anderson Cancer Center, Houston, TXPhone: (713) 794-1477 Dr. Rice is currently concluding enrollment on a Phase II trial of extrapleural pneumonectomy (EPP) followed by Intensity Modulated Radiation Therapy (IMRT). He is also planning a new trial of preoperative Alimta/Cisplatin, followed by EPP and IMRT.
David J. Sugarbaker, MD
Chief, Division of Thoracic Surgery/Brigham and Women's Hospital, Boston, MA Chief, Department of Surgical Services/Dana-Farber Cancer Institute, Boston, MAPhone: (617) 732-6824 Dr. Sugarbaker supports aggressive treatment of pleural mesothelioma. He advocates tri-modal therapy; extrapleural pneumonectomy, chemotherapy and radiation.
Valerie W. Rusch, FACS
Attending Thoracic Surgeon/Memorial-Sloan Kettering Cancer Center, New York, NYPhone: (212) 639-5873 Dr. Rusch is recognized among medical professionals for the treatment of pleural mesothelioma and has written several papers comparing pleural decortication to extrapleural pneumonectomy.
Raja M. Flores, MD
Attending Thoracic Surgeon/Memorial-Sloan Kettering Cancer Center, New York, NYPhone: (212) 639-2806 Dr. Flores works as the Principal Investigator on a clinical trial of neoadjuvant gemcitabine and cisplatin followed by extrapleural pneumonectomy and high dose radiation. He is also involved in a trial of neoadjuvant Alimta/cisplatin, extrapleural pneumonectomy and high dose radiation. He has also compiled a 1,000 patient database to research areas of failure, and how to improve treatments for mesothelioma.
Paul H. Sugarbaker, MD, FACS, FRCS
Director, Surgical Oncology/Washington Cancer Institute, Washington, DCPhone: (202) 877-3908 Dr. Sugarbaker is a specialist in the treatment of peritoneal mesothelioma using a combination of surgery, chemotherapy and radiation.
Brian W. Loggie, MD
Professor of Surgery, Creighton University Medical School; Chief, Division of Surgical Oncology; Director of Cancer Center/Creighton University Medical Center, Omaha, NEPhone: (402) 280-4100 Dr. Loggie specializes in the treatment of peritoneal mesothelioma and peritoneal carcinomatosis. His protocol, based on eligibility, involves surgical debulking in combination with intraperitoneal heated chemotherapy.
Claire F. Verschraegen, MD
Director, Clinical Trial Office and Investigational Drug Program/Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NMPhone: (505) 272-4551Dr. Verschraegen is currently conducting a front-line Alimta/gemcitabine trial for peritoneal mesothelioma patients. She also offers the following Phase I trials for patients who have already been treated with Alimta:
- Phase I Study of Capecitabine with Cisplatin and Irinotecan in Patients with Advanced Malignancies
- Phase I Study of Intravenous TZT-1027 and Gemcitabine, Administered on Day 1 and Day 8 of a Three Week Course in Patients with Advanced Solid Tumors
- Phase I Study of Flavoperidol in Combination with Gemcitabine and Irinotecan in Patients with Metastatic Cancer
